Article title: A prognostic analysis of 895 cases of Stage III colon cancer in different colon subsites

Journal name: International Journal of Colorectal Disease

Author name: Yan Zhang, Junli Ma, Sai Zhang, Ganlu Deng, Xiaoling Wu, Jingxuan He, Haiping Pei, Hong Shen, Shan Zeng

Author’s affiliation: 1 Department of Oncology, 2 Institute of Medical Sciences, 3 Department of Gastrointestinal Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China 410008

Address reprint requests to: Shan Zeng, M.D. & Ph.D., Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China 410008. Tel: (86) 731-8975-3034, Fax: (86) 731-8432-7633, E-mail: zengshan2000@yeah.net
**Fig. 1** Kaplan-Meier analysis of RFS according to ERCC1 expression. (a) Expression of ERCC1 was significantly correlated with poor RFS of colon cancer at all subsites; (b-h) expression of ERCC1 was significantly correlated with poor RFS of site-specific colon cancers (group 1 to 7, respectively).

**Fig. 2** Kaplan-Meier analysis of OS according to ERCC1 expression. (a) Expression of ERCC1 was significantly correlated with poor OS of colon cancer at all subsites; (b-h) expression of ERCC1 was significantly correlated with poor OS of site-specific colon cancers (group 1 to 7, respectively).
Fig. 3 Kaplan-Meier analysis of RFS according to TS expression. (a) Expression of TS exhibited no significant correlation with RFS of colon cancer at all subsites; (b-h) expression of TS exhibited no significant correlation with RFS of site-specific colon cancers (group 1 to 7, respectively).

Fig. 4 Kaplan-Meier analysis of OS according to TS expression. (a) Expression of TS exhibited no significant correlation with OS of colon cancer at all subsites; (b-h) expression of TS exhibited no significant correlation with OS of site-specific colon cancers (group 1 to 7, respectively).
Kaplan-Meier analysis of RFS of stage III colon cancer according to tumor location. A: Compare of RFS of colon cancers site by site. (a) Group 1 versus 2, $P = 0.001$; (b) Group 2 versus 3, $P = 0.017$; (c) Group 3 versus 4, $P = 0.007$; (d) Group 4 versus 5, $P = 0.021$; (e) Group 5 versus 6, $P = 0.036$; (f) Group 6 versus 7, $P = 0.043$. B: Compare of RFS of all other sub-site colon cancers to sigmoid colon cancer respectively. (a) Group 1 versus 7, $P < 0.001$; (b) Group 2 versus 7, $P < 0.001$; (c) Group 3 versus 7, $P < 0.001$; (d) Group 4 versus 7, $P < 0.001$; (e) Group 5 versus 7, $P < 0.001$; (f) Group 6 versus 7, $P = 0.043$.
Fig. 6  Kaplan-Meier analysis of OS of stage III colon cancer according to tumor location. A: Compare of OS of colon cancers site by site. (a) Group 1 versus 2, \( P < 0.001 \); (b) Group 2 versus 3, \( P = 0.026 \); (c) Group 3 versus 4, \( P = 0.017 \); (d) Group 4 versus 5, \( P = 0.047 \); (e) Group 5 versus 6, \( P = 0.024 \); (f) Group 6 versus 7, \( P = 0.003 \).

B: Compare of OS of all other sub-site colon cancers to sigmoid colon cancer respectively. (a) Group 1 versus 7, \( P < 0.001 \); (b) Group 2 versus 7, \( P < 0.001 \); (c) Group 3 versus 7, \( P < 0.001 \); (d) Group 4 versus 7, \( P < 0.001 \); (e) Group 5 versus 7, \( P < 0.001 \); (f) Group 6 versus 7, \( P = 0.003 \).